Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease?

被引：113

作者：

Kapaki, E ^{[1
]}

Kilidireas, K ^{[1
]}

Paraskevas, GP ^{[1
]}

Michalopoulou, M ^{[1
]}

Patsouris, E ^{[1
]}

机构：

[1] Athens Natl Univ, Aeginit Hosp, Sch Med, Dept Neurol, Athens 11528, Greece

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2001年 / 71卷 / 03期

关键词：

Creutzfeldt-Jakob disease; Alzheimer's disease; tau protein; beta-amyloid; 1-42;

D O I：

10.1136/jnnp.71.3.401

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The aim was to quantify tau protein and beta -amyloid (A beta 42) in the CSF of patients with sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double sandwich enzyme linked immunosorbent assays (ELISAs) were used for measurments. Tau was increased 58-fold in CJD and 3.5-fold in AD compared with controls, whereas A beta 42 was decreased 0.5-fold in both CJD and AD. A cut off level for tau protein at 2131 pg/ml successfully discriminated CJD from AD (100% specificity and 93% sensitivity). Tau protein concentration in CSF is probably an additional useful marker in differentiating CJD from AD.

引用

页码：401 / 403

页数：3

共 50 条

[1] CSF tau and amyloid β1-42 (Aβ42) as possible biomarkers of Alzheimer disease
Ravid, R
Kamphorst, W
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S298 - S298
[2] CSF tau protein and β-amyloid (1-42) in Alzheimer's disease diagnosis:: discrimination from normal ageing and other dementias in the Greek population
Kapaki, E
Paraskevas, GP
Zalonis, I
Zournas, C
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (02) : 119 - 128
[3] CSF levels of β-amyloid 1-42, tau and phosphorylated tau protein in CADASIL
Formichi, P.
Parnetti, L.
Radi, E.
Cevenini, G.
Dotti, M. T.
Federico, A.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (11) : 1252 - 1255
[4] Advances in the development of biomarkers for Alzheimer's disease:: from CSF total tau and Aβ1-42 proteins to phosphorylated tau protein
Hampel, H
Goernitz, A
Buerger, K
[J]. BRAIN RESEARCH BULLETIN, 2003, 61 (03) : 243 - 253
[5] CSFβ-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease:: The effect of APOE ε4 allele
Smach, Mohamed Ali
Charfeddine, Bassem
Lammouchi, Turkia
Harrabi, Imed
Ben Othman, Leila
Dridi, Hedi
Bennamou, Soufien
Limem, Khalifa
[J]. NEUROSCIENCE LETTERS, 2008, 440 (02) : 145 - 149
[6] Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
Schoonenboom, NSM
Pijnenburg, YAL
Mulder, C
Rosso, SM
Van Elk, EJ
Van Kamp, GJ
Van Swieten, JC
Scheltens, P
[J]. NEUROLOGY, 2004, 62 (09) : 1580 - 1584
[7] Advances in the development of biomarkers for Alzheimer's disease -: From CSF total tau and amyloid-(β1-42) proteins to phosphorylated tau and amyloid-β-antibodies
Hampel, H
Teipel, S
Faltraco, F
Brettschneider, S
Goernitz, A
Buerger, K
Moeller, HJ
[J]. MOLECULAR NEUROBIOLOGY OF ALZHEIMER DISEASE AND RELATED DISORDERS, 2004, : 134 - 156
[8] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
Hulstaert, F
Blennow, K
Ivanoiu, A
Schoonderwaldt, HC
Riemenschneider, M
De Deyn, PP
Bancher, C
Cras, P
Wiltfang, J
Mehta, PD
Iqbal, K
Pottel, H
Vanmechelen, E
Vanderstichele, H
[J]. NEUROLOGY, 1999, 52 (08) : 1555 - 1562
[9] The diagnostic value of tau protein, β-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages
Kapaki, E
Liappas, I
Paraskevas, GP
Theotoka, I
Rabavilas, A
[J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2005, 20 (08) : 722 - 729
[10] Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease
Pottiez, Gwenael
Yang, Li
Stewart, Tessandra
Song, Ning
Aro, Patrick
Galasko, Douglas R.
Quinn, Joseph F.
Peskind, Elaine R.
Shi, Min
Zhang, Jing
[J]. JOURNAL OF PROTEOME RESEARCH, 2017, 16 (03) : 1228 - 1238

← 1 2 3 4 5 →